Baseline characteristics in relation to osteoporosis<sup>1</sup> before breast cancer diagnosis (BC) in aromatase inhibitor (AI) users.
- Marilyn L. Kwan (244811)
- Joan C. Lo (651313)
- Li Tang (179703)
- Cecile A. Laurent (651314)
- Janise M. Roh (651315)
- Malini Chandra (651316)
- Theresa E. Hahn (651317)
- Chi-Chen Hong (56555)
- Lara Sucheston-Campbell (3721834)
- Dawn L. Hershman (651318)
- Charles P. Quesenberry Jr (651319)
- Christine B. Ambrosone (202037)
- Lawrence H. Kushi (244805)
- Song Yao (202481)
Publication date
October 2014
DOIAbstract
<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.</p>2<p> Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.</p>3<p> Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.</p><p>Baseline characteristics in relation to osteoporosis<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111477#nt107" target="_blank">1</a></sup> before breast cancer diagnosis (BC) in aromatase inhibitor (AI) users.</p
Add to ORKG